Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVE-Lp(a): Muvalaplin for major cardiovascular event reduction in adults with elevated lipoprotein(a)
NL-OMON61069Phase 3Suspended
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Muvalaplin with Placebo (2 arms). Primary endpoint: Time to first occurrence of any component of the major adverse cardiac event (MACE)-4 composite endpoint. Started Nov 2025; status: suspended.
02
Drugs
muvalaplin
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON61069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61069.